SYS-CON MEDIA Authors: Unitiv Blog, Kevin Benedict, Mark R. Hinkle, Glenn Rossman, Jason Bloomberg

News Feed Item

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Geron Corporation - GERN

NEW YORK, March 18, 2014 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Geron Corporation ("Geron" or the "Company") (NasdaqGS: GERN) (CUSIP: 374163103).  Investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 237.

The investigation concerns whether Geron and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

On March 12, 2014, the Company announced that it has received verbal notice from the U.S. Food and Drug Administration ("FDA") that its investigational new drug application for its experimental drug, imetelstat for blood disorders, has been placed on full clinical hold, affecting its mid-stage trials of imetelstat because of low-grade liver function test abnormalities.

On this news, shares of Geron fell $2.71 to $1.69, or more than 61.59%, on unusually heavy trading volume, on March 12, 2014. 

The Pomerantz Firm, with offices in New York, Chicago, San Diego, and Florida, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 70 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:
Robert S. Willoughby
Pomerantz LLP
[email protected]

SOURCE Pomerantz LLP

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.